Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections

Clin Microbiol Infect. 2012 Jan;18(1):54-60. doi: 10.1111/j.1469-0691.2011.03478.x. Epub 2011 Jul 1.

Abstract

The aim of this study was to evaluate the impact of carbapenem-resistant K. pneumoniae bloodstream infections on mortality. During the study period 42, 68 and 120 patients were identified with carbapenem-resistant, extended-spectrum β-lactamase producers (ESBL) and susceptible K. pneumoniae bloodstream infections, respectively. Patients with carbapenem-resistant K. pneumoniae had higher rates of prior antimicrobial exposure, other nosocomial infections, and use of invasive devices. Infection-related mortality was 48% for carbapenem-resistant, 22% for ESBL producers and 17% for susceptible K. pneumoniae. Independent risk factors for infection-related mortality were Pitt bacteraemia score, Charlson score and carbapenem resistance.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems / pharmacology*
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Drug Resistance, Bacterial
  • Female
  • Humans
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / mortality*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / genetics
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Sepsis / drug therapy
  • Sepsis / epidemiology
  • Sepsis / microbiology
  • beta-Lactam Resistance / genetics*

Substances

  • Anti-Bacterial Agents
  • Carbapenems